Skip to content Skip to footer

Anivive Lifesciences Receives $20M Funding from Leonid Capital Partners to Develop Novel Programs for Pets

Shots: Anivive secured a $20M investment from Leonid to advance research of its programs, expand manufacturing, & support the marketing of its valley fever vaccine for canines Funding follows a $33M NIAID contract with NIH to develop human vaccine for the fungus Coccidioides, which causes Valley fever, leading to ~$80M in preorders & contracts…

Read more